tradingkey.logo

Organon & Co

OGN
查看詳細走勢圖
8.210USD
+0.110+1.36%
收盤 02/06, 16:00美東報價延遲15分鐘
2.13B總市值
4.25本益比TTM

Organon & Co

8.210
+0.110+1.36%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.36%

5天

-3.86%

1月

+0.98%

6月

-10.95%

今年開始到現在

+14.50%

1年

-43.84%

查看詳細走勢圖

TradingKey Organon & Co股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Organon & Co當前公司基本面數據相對穩定,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名85/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為9.36。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Organon & Co評分

相關信息

行業排名
85 / 159
全市場排名
229 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

Organon & Co亮點

亮點風險
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
高分紅
公司屬於高分紅公司,最新股息支付率34.38%
估值合理
公司最新PE估值4.25,處於3年歷史合理位
機構減倉
最新機構持股201.61M股,環比減少20.01%
加拿大豐業銀行分紅基金持倉
明星投資者加拿大豐業銀行分紅基金持倉,最新持倉44.51K股

分析師目標

基於 9 分析師
持有
評級
9.357
目標均價
+13.97%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Organon & Co新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Organon & Co簡介

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
公司代碼OGN
公司Organon & Co
CEOMorrissey (Joseph T)
網址https://www.organon.com/
KeyAI